A Chinese biopharma company Huifeng Bio-Pharmaceutical, specializing in producing botanical extracts and other raw materials for pharmaceuticals, announced the reinspection approval of GMP certificate by the State Food and Drug Administration (SFDA) in China. All pharmaceutical companies in China are required by SFDA to gain GMP Certificate for the production of pharmaceuticals.
The implementation of GMP is an effective measure for assuring the quality, safety, and effectiveness of pharmaceutical products. Such GMP certificate is valid for five years. After the validity period has transpired, a full inspection will be conducted by SFDA to check whether the drug manufacturer still meets the GMP requirements. With the rapid development of China's economy, GMP is a forced requirement for Chinese pharmaceutical plants and has become more and more important for those Chinese pharmaceutical companies that want to export their products to the world markets.
"GMP certificate is a rigorous process that we are delighted to have approval of reinspection successfully," said Mr Jing'an Wang, CEO, Huifeng Bio-Pharmaceutical. "The approval of GMP certificate has a significant impact on our company's future success; this further proves the superior quality standards of our products. This certification allows us to move forward to expand not only our domestic market but also our oversea markets, such as in US, India, European countries, Japan and South America as GMP is required by their government."